Literature DB >> 31095842

Cost-effectiveness of the utilization of "good practice" or the lack thereof according to a bronchiolitis evidence-based clinical practice guideline.

Carlos E Rodriguez-Martinez1,2, Monica P Sossa-Briceño3, Jose A Castro-Rodriguez4.   

Abstract

RATIONALE, AIMS, AND
OBJECTIVES: The aim of the present study was to determine the cost-effectiveness of the utilization of "good practice" according to a bronchiolitis clinical practice guideline (CPG) in a population of infants hospitalized for acute bronchiolitis.
METHOD: A decision-analysis model was developed in order to estimate the cost-effectiveness of the utilization of "good practice" compared with the lack of use of "good practice" according to a bronchiolitis evidence-based CPG. The effectiveness parameters and costs of the model were obtained from electronic medical records. The main outcome was the readmission of the patients within 10 days of post discharge.
RESULTS: Compared with lack of "good practice," the utilization of "good practice" in the diagnosis and management of patients with bronchiolitis was associated with both fewer patients readmitted within 10 days of post discharge (0.88 vs 0.99 on average per patient) and lower costs (US$1529.3 versus $1709.1 average cost per patient), thus leading to dominance. Results were robust to deterministic and probabilistic sensitivity analyses.
CONCLUSIONS: Compared with lack of "good practice," the utilization of "good practice" in the diagnosis and management of acute bronchiolitis according to a bronchiolitis CPG is a dominant strategy because it involves both fewer patients readmitted within 10 days of post discharge and lower costs.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  bronchiolitis; clinical practice guidelines; cost-effectiveness; health economics

Mesh:

Year:  2019        PMID: 31095842     DOI: 10.1111/jep.13157

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  5 in total

1.  Families' costs form a considerable part of total costs in bronchiolitis care.

Authors:  Emilia Mäntynen; Sauli Palmu; Paula Heikkilä
Journal:  Health Sci Rep       Date:  2022-04-26

2.  Disability-adjusted life years for respiratory syncytial virus in children under 2 years.

Authors:  Juana Patricia Sánchez Villamil; Fernando P Polack; Jefferson Antonio Buendía
Journal:  BMC Public Health       Date:  2020-11-10       Impact factor: 3.295

3.  Healthcare cost attributable to bronchiolitis: A population-based cohort study.

Authors:  Beate Sander; Yaron Finkelstein; Hong Lu; Chenthila Nagamuthu; Erin Graves; Lauren C Ramsay; Jeffrey C Kwong; Suzanne Schuh
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

4.  Impact of the updating of clinical guidelines for RSV bronchiolitis on the use of diagnostic testing and medications in tertiary hospitals in Colombia.

Authors:  Jefferson Antonio Buendía; Diana Guerrero Patiño
Journal:  Pan Afr Med J       Date:  2022-07-20

5.  Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review.

Authors:  Simon van der Pol; Paula Rojas Garcia; Maarten J Postma; Fernando Antoñanzas Villar; Antoinette D I van Asselt
Journal:  Pharmacoeconomics       Date:  2021-07-15       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.